Vaccines for Antibiotic-Resistant Bacteria: Possibility or Pipe Dream?

Trends in Pharmacological Sciences

Volumn 37, Issue 2, 2016, Pages 143-152

  García Quintanilla, Meritxell ^a   Pulido, Marina R ^a   Carretero Ledesma, Marta ^a   McConnell, Michael J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

antibiotic resistance; antigen identification; clinical trials; passive immunization; vaccine

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL VACCINE; CARBAPENEM DERIVATIVE; CEFTAZIDIME; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PSEUDOMONAS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; V 710;

ACINETOBACTER BAUMANNII; ACTIVE IMMUNIZATION; ANTIBIOTIC RESISTANCE; ANTIGEN EXPRESSION; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GENOMICS; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION; INFECTION RATE; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MORBIDITY; MORTALITY; NEXT GENERATION SEQUENCING; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGEN LOAD; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; SERODIAGNOSIS; SITE DIRECTED MUTAGENESIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TRANSCRIPTOMICS; TREATMENT CONTRAINDICATION; UNITED STATES; VACCINATION; BACTERIAL INFECTIONS; CHEMISTRY; GENETICS; IMMUNOLOGY; MICROBIOLOGY;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 84955466451     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.10.003     Document Type: Review

References (79)

1. World Health Organization Antibiotic Resistance: Global Report on Surveillance 2014 2014 World Health Organization
2. C. Suetens, and et al. Point Prevalance Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals 2013 European Centers for Disease Prevention and Control
3. Centers for Disease Control and Prevention Threat Report 2013: Antibiotic/Antimicrobial Resistance 2013 Centers for Disease Control and Prevention
4. R.R. Roberts, and et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship Clin. Infect. Dis. 49 2009 1175 1184
5. M.A. Cooper, and D. Shlaes Fix the antibiotics pipeline Nature 472 2011 32
6. K. Servick The drug push Science 348 2015 850 853
7. Transatlantic Taskforce on Antimicrobial Resistance Recommendations for Resistance 2011 Transatlantic Taskforce on Antimicrobial Resistance
8. C. Gagliotti, and et al. A regionwide intervention to promote appropriate antibiotic use in children reversed trends in erythromycin resistance to Streptococcus pyogenes Acta Paediatr. 104 2015 e422 e424
9. H. Goossens, and et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study Lancet 365 2005 579 587
10. N. van de Sande-Bruinsma, and et al. Antimicrobial drug use and resistance in Europe Emerg. Infect. Dis. 14 2008 1722 1730
11. M. Sundqvist, and et al. Within-population distribution of trimethoprim resistance in Escherichia coli before and after a community-wide intervention on trimethoprim use Antimicrob. Agents Chemother. 58 2014 7492 7500
12. F.A. Heinsen, and et al. Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin Gut Microbes 6 2015 243 254
13. A.M. Schubert, and et al. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile MBio 2015 e00974-15
14. A.J. Stewardson, and et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota Clin. Microb. Infect. 21 2015 344 e341-e344
15. F. Fouhy, and et al. Identification of aminoglycoside and beta-lactam resistance genes from within an infant gut functional metagenomic library PLoS ONE 9 2014 e108016
16. Y. Hu, and et al. Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota Nat. Commun. 4 2013 2151
17. N. Lu, and et al. DNA microarray analysis reveals that antibiotic resistance-gene diversity in human gut microbiota is age related Sci. Rep. 4 2014 4302
18. J.J. Hilliard, and et al. Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model Antimicrob. Agents Chemother. 59 2015 299 309
19. M.J. McConnell, and et al. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii Infect. Immun. 79 2011 518 526
20. Y.A. Que, and et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia Eur. J. Clin. Microbiol. Infect. Dis. 33 2014 1861 1867
21. I. Lowy, and et al. Treatment with monoclonal antibodies against Clostridium difficile toxins N. Engl. J. Med. 362 2010 197 205
22. A.S. Cross, and et al. A case for immunization against nosocomial infections J. Leukoc. Biol. 83 2008 483 488
23. L.B. Lawson, and et al. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity Curr. Opin. Immunol. 23 2011 414 420
24. P. Riese, and et al. Intranasal formulations: promising strategy to deliver vaccines Expert Opin. Drug Deliv. 11 2014 1619 1634
25. F.E. Andre How the research-based industry approaches vaccine development and establishes priorities Dev. Biol. 110 2002 25 29
26. M. Goldman, and et al. The Innovative Medicines Initiative: an engine for regulatory science Nat. Rev. Drug Discov. 14 2015 1 2
27. V.G. Fowler Jr, and R.A. Proctor Where does a Staphylococcus aureus vaccine stand? Clin. Microbiol. Infect. 20 Suppl. 5 2014 66 75
28. J.L. Vincent Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update Future Microbiol. 9 2014 457 463
29. T.A. Ahmad, and et al. Development of immunization trials against Klebsiella pneumoniae Vaccine 30 2012 2411 2420
30. M. Garcia-Quintanilla, and et al. First steps towards a vaccine against Acinetobacter baumannii Curr. Pharm. Biotechnol. 14 2013 897 902
31. R. Leuzzi, and et al. Vaccines against Clostridium difficile Hum. Vaccin. Immunother. 10 2014 1466 1477
32. D.M. Sievert, and et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 Infect. Control Hosp. Epidemiol. 34 2013 1 14
33. F.D. Lowy Staphylococcus aureus infections N. Engl. J. Med. 339 1998 520 532
34. P. Moreillon, and et al. Staphylococcus aureus (including staphylococcal toxic shock) G.L. Mandell, Principles and Practice of Infectious Diseases 6th edn 2005 Elsevier 2321 2351
35. G. Sakoulas, and R.C. Moellering Jr Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains Clin. Infect. Dis. 46 Suppl. 5 2008 S360 S367
36. A.M. Spagnolo, and et al. Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings J. Prev. Med. Hyg. 55 2014 137 144
37. A. Fattom, and et al. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study Hum. Vaccin. Immunother. 11 2015 632 641
38. B. Spellberg, and R. Daum Development of a vaccine against Staphylococcus aureus Semin. Immunopathol. 34 2012 335 348
39. D.K. Benjamin, and et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin J. Perinatol. 26 2006 290 295
40. M.E. Rupp, and et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia Antimicrob. Agents Chemother. 51 2007 4249 4254
41. V.G. Fowler, and et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial JAMA 309 2013 1368 1378
42. M. DeJonge, and et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants J. Pediatr. 151 2007 260 265
43. L.E. Weisman, and et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates Antimicrob. Agents Chemother. 53 2009 2879 2886
44. R.J. Jones, and et al. Low mortality in burned patients in a Pseudomonas vaccine trial Lancet 2 1978 401 403
45. R.J. Jones, and et al. Controlled trials of a polyvalent Pseudomonas vaccine in burns Lancet 2 1979 977 982
46. D.T. Langford, and J. Hiller Prospective, controlled study of a polyvalent Pseudomonas vaccine in cystic fibrosis - three year results Arch. Dis. Child. 59 1984 1131 1134
47. J.E. Pennington, and et al. Use of a Pseudomonas aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis Am. J. Med. 58 1975 629 636
48. A.B. Lang, and et al. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection Pediatr. Infect. Dis. J. 23 2004 504 510
49. M. Hogardt, and J. Heesemann Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung Int. J. Med. Microbiol. 300 2010 557 562
50. G.B. Pier, and et al. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine Infect. Immun. 62 1994 3972 3979
51. G. Doring, and et al. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients Proc. Natl. Acad. Sci. U.S.A. 104 2007 11020 11025
52. M.J. Rosok, and et al. Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa Infect. Immun. 58 1990 3819 3828
53. A.H. Tart, and et al. The AlgT-dependent transcriptional regulator AmrZ (AlgZ) inhibits flagellum biosynthesis in mucoid, nonmotile Pseudomonas aeruginosa cystic fibrosis isolates J. Bacteriol. 188 2006 6483 6489
54. K. Westritschnig, and et al. A randomized, placebo-controlled Phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers Hum. Vaccin. Immunother. 10 2014 170 183
55. U. Bruderer, and et al. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients J. Infect. Dis. 166 1992 344 349
56. O. Ciofu, and et al. Avidity of anti-P. aeruginosa antibodies during chronic infection in patients with cystic fibrosis Thorax 54 1999 141 144
57. S.A. Fritz, and et al. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection Clin. Infect. Dis. 56 2013 1554 1561
58. S. Delfani, and et al. Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA-IsdB-Hlg as a vaccine candidate Med. Microbiol. Immunol. 2015 10.1007/s00430-015-0425 Published online July 9, 2015
59. A. Farjaha, and et al. Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against Pseudomonas aeruginosa J. Biotechnol. 192 2014 240 247
60. I.D. Golpasha, and et al. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa Bosn J. Basic Med. Sci. 15 2015 15 24
61. S.M. Lattar, and et al. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis Infect. Immun. 82 2014 83 91
62. B.Z. Zhang, and et al. Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model Infect. Immun. 83 2015 339 345
63. M.H. Chiang, and et al. Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology Hum. Vaccin. Immunother. 11 2015 1065 1073
64. A.P. Chan, and et al. A novel method of consensus pan-chromosome assembly and large-scale comparative analysis reveal the highly flexible pan-genome of Acinetobacter baumannii Genome Biol. 16 2015 143
65. R.G. Everitt, and et al. Mobile elements drive recombination hotspots in the core genome of Staphylococcus aureus Nat. Commun. 5 2014 3956
66. B. Valot, and et al. What it takes to be a Pseudomonas aeruginosa? The core genome of the opportunistic pathogen updated PLoS ONE 10 2015 e0126468
67. N. Wang, and et al. Genome-wide identification of Acinetobacter baumannii genes necessary for persistence in the lung MBio 5 2014 e01163-14
68. D. Skurnik, and et al. A comprehensive analysis of in vitro and in vivo genetic fitness of Pseudomonas aeruginosa using high-throughput sequencing of transposon libraries PLoS Pathog. 9 2013 e1003582
69. C.J. Jones, and et al. ChIP-seq and RNA-seq reveal an AmrZ-mediated mechanism for cyclic di-GMP synthesis and biofilm development by Pseudomonas aeruginosa PLoS Pathog. 10 2014 e1003984
70. S. Rumbo-Feal, and et al. Whole transcriptome analysis of Acinetobacter baumannii assessed by RNA-sequencing reveals different mRNA expression profiles in biofilm compared to planktonic cells PLoS ONE 8 2013 e72968
71. A.K. Szafranska, and et al. High-resolution transcriptomic analysis of the adaptive response of Staphylococcus aureus during acute and chronic phases of osteomyelitis MBio 5 2014 e01775-14
72. X. Tan, and et al. Transcriptome analysis of the biofilm formed by methicillin-susceptible Staphylococcus aureus Sci. Rep. 5 2015 11997
73. J. Blonder, and et al. Global analysis of the membrane subproteome of Pseudomonas aeruginosa using liquid chromatography-tandem mass spectrometry J. Proteome Res. 3 2004 434 444
74. A.J. Brinkworth, and et al. Identification of outer membrane and exoproteins of carbapenem-resistant multilocus sequence Type 258 Klebsiella pneumoniae PLoS ONE 10 2015 e0123219
75. J.A. Mendez, and et al. Extracellular proteome of a highly invasive multidrug-resistant clinical strain of Acinetobacter baumannii J. Proteome Res. 11 2012 5678 5694
76. S.H. Yun, and et al. Quantitative proteomic analysis of cell wall and plasma membrane fractions from multidrug-resistant Acinetobacter baumannii J. Proteome Res. 10 2011 459 469
77. A. Olaya-Abril, and et al. Surfomics: shaving live organisms for a fast proteomic identification of surface proteins J. Proteomics 97 2014 164 176
78. A. Olaya-Abril, and et al. Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults PLoS ONE 8 2013 e70365
79. M.J. Rodriguez-Ortega, and et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome Nat. Biotechnol. 24 2006 191 197